Navigation Links
Angiotech wins before the UK House of Lords
Date:7/10/2008

VANCOUVER, July 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced that yesterday, the highest court of the United Kingdom, the House of Lords, confirmed in a precedent-setting decision the validity of one of Angiotech's patents related to its paclitaxel stent inventions. As Lord Neuberger of Abbotsbury, commented, "The decision represents a significant development in the United Kingdom patent law".

"We are pleased that the House of Lords entered final judgment in Angiotech's favor and view this outcome as further proof of the continued strength of our paclitaxel stent patent portfolio throughout the world," said Dr. Bill Hunter, President and CEO of Angiotech. "We remain committed to vigorously protecting our proprietary technologies and defending our intellectual property, and reaching supportive conclusion on this decision reaffirms this commitment," added Dr. Hunter.

The patent at issue was granted to Angiotech Pharmaceuticals Inc. by the European Patent Office (the "EPO") on June 25, 1997. At the EPO, five different companies opposed the patent. After over nine years of legal battles their challenge proved unsuccessful and the validity of the patent was maintained. On February 1, 2005, Angiotech commenced suit against Conor Medsystems Inc. ("Conor") in the Netherlands. Conor responded by commencing proceedings in the UK to revoke the patent. Conor argued that, as of July 1993 (the priority date), the claims in the patent lacked inventive step (i.e., were obvious) under UK law.

Both the UK trial court and the UK Court of Appeal decided that the patent was invalid in view of several publications. Within the sa
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... FRANCISCO, Calif., March 14 ,Renovis, Inc. (Nasdaq: RNVS ... of drugs for major medical needs in the areas ... fourth quarter and year ended December 31, 2007., ... December 31, 2007 was,$1.3 million and $9.8 million, respectively, ...
... MADISON, N.J., March 14 Quest Diagnostics,Incorporated (NYSE: ... diagnostic,testing, information and services, announced that it is ... Global Healthcare Conference on,Wednesday, March 19, 2008, at ... Diagnostics presentation is scheduled to begin at 9:00 ...
... NuVasive, Inc. (Nasdaq:,NUVA), a medical device company focused on ... announced today,that Kevin O,Boyle, Executive Vice President and Chief ... Eleventh Annual Global,Healthcare Conference at the Loews Miami Beach ... at 10:15 a.m. ET., A live Web cast ...
Cached Biology Technology:Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 3Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 4Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 5Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 6Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 7Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3
(Date:5/17/2013)... study finds human-caused climate change may have little ... a host of recent studies that predict their ... The findings, which appear in the journal ... survival of a creature thought to be doomed: ... cold-blooded animals, especially forest lizards, will be hard ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Endocrine Society (ENDO) 95th Annual Meeting in San ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... ENDO 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... scientists have shown a gene involved in neurodegenerative disease ... of the circadian clock. , In a study ... gene, called Ataxin-2, keeps the clock responsible for sleeping ... the rhythm of the fruit fly,s sleep-wake cycle is ... for the fly. , The discovery is particularly ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Gene involved in neurodegeneration keeps clock running 2
... a new technique for the in vivo imaging of ... protein. This imaging technique enables the monitoring of neuronal ... in either a small group of neurons or in ... the development were The Molecular Embryology Unit (CNRS/Institut Pasteur) ...
... de sustancias antagonistas producidas por microorganismos" (Antagonistic substances ... of the University of Granada (Universidad de Granada ... AS-48, which could have a medium-term use as ... that biopreservation is an innovative method in food-preservation ...
... In laboratory tests on mice, researchers found that a ... chemotherapy induced bone loss and helped tumors grow in ... Medicine in St. Louis are recommending increased awareness of ... studied is a growth factor commonly used to help ...
Cached Biology News:Bioluminescence at the service of a novel cerebral imaging technique 2Bioluminescence at the service of a novel cerebral imaging technique 3Researchers from the UGR use a bacterium to obtain biopreservatives from food 2Researchers urge monitoring of bone health during chemotherapy 2Researchers urge monitoring of bone health during chemotherapy 3